The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:

OBJECTIVE: The authors’ goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D2 receptor occupancy in stabilized patients with schizophrenia.METHOD: Subjective experience, psychopathology, and extrapyramidal symptoms were assessed, and D2 receptor occupancy was determined with [123I]iodobenzamide single photon emission computed tomography, in 22 patients whose schizophrenia was stabilized by olanzapine or risperidone.RESULTS: Subjective experience, depression, and negative symptoms were related to dopamine D2 receptor occupancy, but extrapyramidal symptoms were not.CONCLUSIONS: These results provide preliminary evidence that negative subjective experience is related to high D2 receptor occupancy. Longitudinal study is required because this relationship may have implications for dosing strategies.